Baseline characteristics of the patients according to the severity of tricuspid regurgitation
| Total population (n=209) | Moderate TR (n=123) | Severe TR (n=86) | P value | |
| Age (year) | 72±14 | 72±14 | 72±14 | 0.742 |
| Male/female (%) | 44/56 | 46/54 | 41/59 | 0.419 |
| Height (m) | 1.66±0.10 | 1.66±0.10 | 1.65±0.15 | 0.370 |
| Weight (kg) | 71±16 | 74±17 | 68±15 | 0.015 |
| Body mass index (kg/m2) | 26.0±5.4 | 26.7±5.8 | 24.8±4.5 | 0.028 |
| Systolic blood pressure (mm Hg) | 134±20 | 135±20 | 132±20 | 0.435 |
| Diastolic blood pressure (mm Hg) | 73±12 | 73±12 | 72±12 | 0.664 |
| Diabetes (%) | 31 | 38 | 21 | 0.015 |
| Hypertension (%) | 84 | 80 | 92 | 0.028 |
| Hypercholesterolaemia (%) | 69 | 71 | 65 | 0.382 |
| Smoking (%) | 34 | 33 | 34 | 0.919 |
| Coronary artery disease (%) | 48 | 50 | 46 | 0.602 |
| Overall atrial fibrillation (%) | 78 | 75 | 82 | 0.250 |
| Chronic lung disease (%) | 14 | 18 | 8 | 0.042 |
| Pacemaker or ICD at baseline (%) | 26 | 26 | 26 | 0.983 |
| Overall pacemaker or ICD (%) | 31 | 31 | 31 | 0.963 |
| Baseline LVEF (%) | 49±14 | 50±14 | 50±14 | 0.771 |
| Baseline LVEF≤40% (%) | 23 | 22 | 26 | 0.542 |
| Baseline TAPSE (mm) | 18.3±5.5 | 18.5±5.0 | 17.9±6.0 | 0.466 |
| RV (S’) (cm/s) | 11.3±3.4 | 11.6±3.5 | 10.8±3.2 | 0.281 |
| RV dysfunction at baseline (%) | 43 | 41 | 47 | 0.440 |
| RV systolic pressure (mm Hg) | 36±15 | 37±13 | 36±17 | 0.850 |
| Right atrial pressure (mm Hg) | 11±6 | 10±6 | 12±6 | 0.07 |
| SPAP (mm Hg) | 47±16 | 47±16 | 47±18 | 0.873 |
| Pulmonary hypertension (%) | 66 | 63 | 70 | 0.340 |
| RV basal diameter (cm) | 4.2±0.6 | 4.1±0.5 | 4.7±0.6 | <0.001 |
| Right atrium end-systolic area (cm2) | 28±9 | 27±8 | 30±10 | 0.002 |
| Right atrium annular dilatation (%) | 74 | 68 | 83 | 0.020 |
| Vena contracta (mm) | 7.8±3.2 | 5.7±1.4 | 9.0±3.2 | 0.005 |
| Tricuspid valve replacement (%) | 6.2 | 2.4 | 11.6 | 0.007 |
| Mitral valve replacement (%) | 19 | 16 | 23 | 0.216 |
| Aortic valve replacement (%) | 22 | 24 | 19 | 0.389 |
| Significant left-sided VHD (%) | 45 | 42 | 49 | 0.348 |
| Moderate or severe MR (%) | 39 | 37 | 43 | 0.348 |
| Moderate or severe MS (%) | 6 | 7 | 6 | 0.839 |
| Moderate or severe AR (%) | 6 | 5 | 8 | 0.337 |
| Moderate or severe AS (%) | 9 | 8 | 9 | 0.766 |
| Mean follow-up (months) | 70±33 | 68±34 | 71±32 | 0.567 |
| Deaths during follow-up (%) | 59 | 61 | 56 | 0.456 |
AR, aortic regurgitation; AS, aortic stenosis;ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MS, mitral stenosis;RV, right ventricle/ventricular;SPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion;TR, tricuspid regurgitation; VHD, valvular heart disease.